Key Takeaways
- • TA Associates is set to take a majority stake in MedEnvision, a Benelux-based healthcare company currently backed by Smile Invest, according to PEI Private Equity.
- • MedEnvision develops products that standardize hip, knee and shoulder replacement procedures, aiming to help hospitals run operating theaters more efficiently.
- • The source material does not disclose the deal value, the size of the stake retained by Smile Invest, or the expected closing timeline.
Summary
TA Associates is set to acquire a majority stake in MedEnvision, a healthcare company backed by Smile Invest, according to a PEI Private Equity report published by PE Hub. The transaction is categorized within the deals coverage for the Benelux region and European healthcare sector.
MedEnvision develops products that standardize hip, knee and shoulder replacement procedures. The company's offerings are designed to help hospitals run operating theaters more efficiently, addressing a recurring operational priority for orthopedic surgery providers as procedure volumes continue to rise.
The available source material does not specify the transaction value, the proportion of the company that Smile Invest will retain, or the anticipated closing date. Readers seeking those terms should consult subsequent filings or deal announcements from the parties involved.
MedEnvision develops products that standardize hip, knee and shoulder replacement procedures. The company's offerings are designed to help hospitals run operating theaters more efficiently, addressing a recurring operational priority for orthopedic surgery providers as procedure volumes continue to rise.
The available source material does not specify the transaction value, the proportion of the company that Smile Invest will retain, or the anticipated closing date. Readers seeking those terms should consult subsequent filings or deal announcements from the parties involved.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.